Raveron versus placebo in the conservative treatment of benign prostatic hyperplasia (BPH)

K Bircan; H A Ozen; A Ergen; I Başar; S Ozgür; Y Ilker; E Karaağaoğlu; D Remzi

doi:10.1007/BF02549794

Raveron versus placebo in the conservative treatment of benign prostatic hyperplasia (BPH)

Int Urol Nephrol. 1990;22(4):345-8. doi: 10.1007/BF02549794.

Authors

K Bircan¹, H A Ozen, A Ergen, I Başar, S Ozgür, Y Ilker, E Karaağaoğlu, D Remzi

Affiliation

¹ Department of Urology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

PMID: 1699907
DOI: 10.1007/BF02549794

Abstract

Thirty patients with BPH were randomized into two groups to receive Raveron and placebo for 6 weeks. The subjective and objective signs associated with BPH were evaluated before and after treatment. There was no significant difference between the effects of Raveron and placebo.

Publication types

Clinical Trial
Randomized Controlled Trial

MeSH terms

Double-Blind Method
Humans
Male
Middle Aged
Placebos
Prospective Studies
Prostatic Hyperplasia / drug therapy*
Tissue Extracts / therapeutic use*
Urodynamics / drug effects

Substances

Placebos
Robaveron
Tissue Extracts